Corneal Sensitivity Cross-linking Keratoconus

Inclusion Criteria: * Be at least 18 years of age * Provide written consent and sign a HIPAA form * Willingness and ability to follow all instructions and comply with schedule for follow-up visits * For females capable of becoming pregnant,agreet o have uurine pregnancy testing performed prior to treatment; must not be lactating, and must agree to use a medically acceptable form of birth control for at least one week prior to the treatment and continue to use the method until 1 month after the last dose of investigational product. * Having topographic evidence of keratoconus which is graded as lower stage progressive keratoconus * Presence of central or inferior steepening on the Pentacam map * Steepest keratometry (Kmax) value greater than or equal to 51.00D * BSCVA of 80 letters or fewer for keratoconus on ETDRS chart * Contact lens wearers only: remove contact lenses one week prior to the screening refraction * Contact lens wearers only: manifest refraction must be stable between two visits that occur at least 7 days apart Exclusion Criteria: * Contraindications, sensitivity or known allergy to the use of the test articles(S) or their components * If female, be pregnant, nursing, or planning a pregnancy or have a positive urine pregnancy test at Visit 2 prior to treatment or during the course of the study * Eyes classified as either normal,atypical normal,keratoconus suspect or mild keratoconus on the severity grading scheme * A history of the insertion of INTACS in the eye to be treated * A history of previous limbal relaxing incision procedure in the eye to be treated * Corneal pachymetry that is \<350 microns at the thinnest point measured by Pentacam in the eye to be treated * Eyes which are aphakic * Eyes which are pseudophakic and do not have a UV blocking lens implanted * Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. * A history of delayed epithelial healing in the eye to be treated * Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests * Patients with a currnet condition that, in the investigator's opinion,would interfere with or prolong epithelial healing * Taking Vitamin C (ascorbic acid) supplements within 1 week of the crosslinking treatment * A history of previous corneal crosslinking treatment in the eye to be treated * Have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study